Celestia S. Higano
Fred Hutchinson Cancer Research Center
465 Papers
3.4K Citations
Celestia S. Higano is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 78, co-authored 423 publications. Previous affiliations of Celestia S. Higano include United States Department of Veterans Affairs & Ohio State University.
Chat about Author
Papers
Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results
Martine Roudier,Hubert Vesselle,Larry True,Celestia S. Higano,Susan M. Ott,Susan M. Ott,S. H. King,Robert L. Vessella,Robert L. Vessella +8 more
TL;DR: Long-term pamidronate treatment of prostate cancerBone metastases does not generally affect the ability to detect bone metastases with Tc99 MDP bone scintigraphy, and there was no statistical difference between the treated and non-treated group for concordance, specificity, sensitivity, positive and negative predictive values of bone scINTigraphy and prevalence of histological abnormality.
Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.
Tomasz M. Beer,Andrew J. Armstrong,Cora N. Sternberg,Celestia S. Higano,Peter Iversen,Yohann Loriot,Dana E. Rathkopf,Suman Bhattacharya,Joan Carles,Johann S. de Bono,Christopher P. Evans,Anthony M. Joshua,Choung-Soo Kim,Go Kimura,Paul N. Mainwaring,Harry H. Mansbach,Kurt Miller,Sarah B. Noonberg,Peter Venner,Bertrand Tombal +19 more
TL;DR: This study examined whether enzalutamide could prolong OS and radiographic progression-free survival (rPFS) in asymptomatic or mildly symptomatic chemotherapy-naive men with mCRPC and found it had sufficient power to detect a target OS hazard ratio of 0.57.
Histologic Changes Associated With Neoadjuvant Chemotherapy Are Predictive of Nodal Metastases in Patients With High-Risk Prostate Cancer
Catherine A. O’Brien,Lawrence D. True,Celestia S. Higano,Brooks L. S. Rademacher,Mark Garzotto,Mark Garzotto,Tomasz M. Beer +6 more
TL;DR: Intraductal and cribriform histologic features apparently predict postchemotherapy outcome in men with high-risk prostate cancer treated with preprostatectomy docetaxel and mitoxantrone.
Comparing virtual and in-person training for intracavernosal injection therapy in a multidisciplinary sexual health clinic within a prostate cancer survivorship program
Sania Julian,Rosalie Ho,C. Zarowski,Meghan Lui,I. Yu,Maria Daniella Sare,Monita Sundar,Celestia S. Higano,Ryan Flannigan +8 more